Close

CytRx (CYTR) Presents Significant Aldoxorubicin Phase 2b Data

August 7, 2014 6:09 AM EDT Send to a Friend
CytRx (Nasdaq: CYTR) announced that its oral presentation given by Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login